Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting.

Alshaker H, Wang Q, Brewer D, Pchejetski D.

Front Pharmacol. 2019 Mar 27;10:303. doi: 10.3389/fphar.2019.00303. eCollection 2019.

2.

Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.

Alshaker H, Srivats S, Monteil D, Wang Q, Low CMR, Pchejetski D.

Breast Cancer Res Treat. 2018 Nov;172(1):33-43. doi: 10.1007/s10549-018-4900-1. Epub 2018 Jul 24.

3.

Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer.

Wang Q, Alshaker H, Böhler T, Srivats S, Chao Y, Cooper C, Pchejetski D.

Sci Rep. 2017 Jul 19;7(1):5901. doi: 10.1038/s41598-017-06142-x.

4.

New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth.

Alshaker H, Wang Q, Srivats S, Chao Y, Cooper C, Pchejetski D.

Breast Cancer Res Treat. 2017 Oct;165(3):531-543. doi: 10.1007/s10549-017-4380-8. Epub 2017 Jul 10.

5.

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.

Alshaker H, Wang Q, Böhler T, Mills R, Winkler M, Arafat T, Kawano Y, Pchejetski D.

Sci Rep. 2017 Jun 14;7(1):3493. doi: 10.1038/s41598-017-03728-3.

6.

An unusual case of disseminated intravascular coagulation.

Pchejetski D, Kenbaz M, Alshaker H, Rajput D, Jesudason K.

Oxf Med Case Reports. 2017 Apr 3;2017(4):omx009. doi: 10.1093/omcr/omx009. eCollection 2017 Apr.

7.

Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.

Alshaker H, Wang Q, Kawano Y, Arafat T, Böhler T, Winkler M, Cooper C, Pchejetski D.

Oncotarget. 2016 Dec 6;7(49):80943-80956. doi: 10.18632/oncotarget.13115.

8.

Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer.

Sacco K, Muhammad A, Saleem W, Alshaker H, Monzon L, Islam MR, Pchejetski D.

Oncol Lett. 2016 Aug;12(2):779-782. Epub 2016 Jun 16.

9.

The emerging role of FTY720 (Fingolimod) in cancer treatment.

White C, Alshaker H, Cooper C, Winkler M, Pchejetski D.

Oncotarget. 2016 Apr 26;7(17):23106-27. doi: 10.18632/oncotarget.7145. Review.

10.

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.

Pchejetski D, Alfraidi A, Sacco K, Alshaker H, Muhammad A, Monzon L.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1659-71. doi: 10.1007/s00432-015-2064-5. Epub 2015 Nov 11. Review.

11.

Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma.

Alshaker H, Sacco K, Alfraidi A, Muhammad A, Winkler M, Pchejetski D.

Oncotarget. 2015 Nov 3;6(34):35556-63. doi: 10.18632/oncotarget.5574. Review.

12.

Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.

Alshaker H, Krell J, Frampton AE, Waxman J, Blyuss O, Zaikin A, Winkler M, Stebbing J, Yagüe E, Pchejetski D.

Breast Cancer Res. 2014 Oct 25;16(5):426. doi: 10.1186/s13058-014-0426-6.

13.

Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer.

Alshaker H, Wang Q, Frampton AE, Krell J, Waxman J, Winkler M, Stebbing J, Cooper C, Yagüe E, Pchejetski D.

Breast Cancer Res Treat. 2015 Jan;149(1):59-67. doi: 10.1007/s10549-014-3228-8. Epub 2014 Dec 7.

PMID:
25481644
14.

Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.

Annels NE, Simpson GR, Denyer M, McGrath SE, Falgari G, Killick E, Eeles R, Stebbing J, Pchejetski D, Cutress R, Murray N, Michael A, Pandha H.

Clin Exp Immunol. 2014 Aug;177(2):428-38. doi: 10.1111/cei.12332.

15.

Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation.

Pinho FG, Frampton AE, Nunes J, Krell J, Alshaker H, Jacob J, Pellegrino L, Roca-Alonso L, de Giorgio A, Harding V, Waxman J, Stebbing J, Pchejetski D, Castellano L.

Cancer Res. 2013 Oct 1;73(19):5936-48. doi: 10.1158/0008-5472.CAN-13-0158. Epub 2013 Aug 8.

16.

Therapeutic potential of targeting SK1 in human cancers.

Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Böhler T, Pchejetski D.

Adv Cancer Res. 2013;117:143-200. doi: 10.1016/B978-0-12-394274-6.00006-6. Review.

PMID:
23290780
17.

Differential control of hypoxia-inducible factor 1 activity during pro-inflammatory reactions of human haematopoietic cells of myeloid lineage.

Gibbs BF, Yasinska IM, Pchejetski D, Wyszynski RW, Sumbayev VV.

Int J Biochem Cell Biol. 2012 Nov;44(11):1739-49. doi: 10.1016/j.biocel.2012.06.019. Epub 2012 Jun 21.

PMID:
22728164
18.

Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection.

Nunes J, Naymark M, Sauer L, Muhammad A, Keun H, Sturge J, Stebbing J, Waxman J, Pchejetski D.

Br J Cancer. 2012 Feb 28;106(5):909-15. doi: 10.1038/bjc.2012.14. Epub 2012 Feb 7.

19.

TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis.

Caley MP, Kogianni G, Adamarek A, Gronau JH, Rodriguez-Teja M, Fonseca AV, Mauri F, Sandison A, Rhim JS, Pchejetski D, Palmieri C, Cobb JP, Waxman J, Sturge J.

J Pathol. 2012 Apr;226(5):775-83. doi: 10.1002/path.3958. Epub 2011 Dec 8. Erratum in: J Pathol. 2013 Feb;229(3):e4. Pchejetski, Dmitri [added].

PMID:
22072289
20.

Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1.

Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH, Wanecq E, Valet P, Parini A, Kunduzova O.

Eur Heart J. 2012 Sep;33(18):2360-9. doi: 10.1093/eurheartj/ehr389. Epub 2011 Oct 25.

PMID:
22028387
21.

Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Pchejetski D, Böhler T, Stebbing J, Waxman J.

Nat Rev Urol. 2011 Sep 13;8(10):569-678. doi: 10.1038/nrurol.2011.117. Review.

PMID:
21912422
22.

A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy.

Stebbing J, Sharma A, North B, Athersuch TJ, Zebrowski A, Pchejetski D, Coombes RC, Nicholson JK, Keun HC.

Ann Oncol. 2012 Apr;23(4):860-6. doi: 10.1093/annonc/mdr347. Epub 2011 Aug 4.

23.

Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens.

Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P, Cuvillier O.

Eur J Cancer. 2010 Dec;46(18):3417-24. doi: 10.1016/j.ejca.2010.07.053. Epub 2010 Oct 20.

PMID:
20970322
24.

FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.

Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, Cuvillier O.

Cancer Res. 2010 Nov 1;70(21):8651-61. doi: 10.1158/0008-5472.CAN-10-1388. Epub 2010 Oct 19.

25.

The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1α protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6.

Pchejetski D, Nunes J, Coughlan K, Lall H, Pitson SM, Waxman J, Sumbayev VV.

Immunol Cell Biol. 2011 Feb;89(2):268-74. doi: 10.1038/icb.2010.91. Epub 2010 Jul 27.

PMID:
20661259
26.

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.

Henry NL, Pchejetski D, A'Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Stebbing J.

Br J Cancer. 2010 Jul 27;103(3):291-6. doi: 10.1038/sj.bjc.6605768. Epub 2010 Jul 6.

27.

Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer.

Pchejetski D, Nunes J, Sauer L, Sidhu J, Sharma A, Keun HC, Waxman J, Stebbing J.

Breast Cancer Res Treat. 2010 Nov;124(2):543-9. doi: 10.1007/s10549-010-0968-y. Epub 2010 Jun 10.

PMID:
20535545
28.

Serum molecular signatures of weight change during early breast cancer chemotherapy.

Keun HC, Sidhu J, Pchejetski D, Lewis JS, Marconell H, Patterson M, Bloom SR, Amber V, Coombes RC, Stebbing J.

Clin Cancer Res. 2009 Nov 1;15(21):6716-23. doi: 10.1158/1078-0432.CCR-09-1452. Epub 2009 Oct 27.

29.

Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.

Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J, Pchejetski D.

Int J Cancer. 2009 Dec 1;125(11):2728-36. doi: 10.1002/ijc.24640.

30.

Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.

Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C.

Mol Cancer Ther. 2009 Apr;8(4):809-20. doi: 10.1158/1535-7163.MCT-08-1096.

31.

Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.

Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, Waxman J, Malavaud B, Cuvillier O.

Mol Cancer Ther. 2008 Jul;7(7):1836-45. doi: 10.1158/1535-7163.MCT-07-2322.

32.

Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide.

Gomez-Brouchet A, Pchejetski D, Brizuela L, Garcia V, Altié MF, Maddelein ML, Delisle MB, Cuvillier O.

Mol Pharmacol. 2007 Aug;72(2):341-9. Epub 2007 May 23.

PMID:
17522181
33.

Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis.

Pchejetski D, Kunduzova O, Dayon A, Calise D, Seguelas MH, Leducq N, Seif I, Parini A, Cuvillier O.

Circ Res. 2007 Jan 5;100(1):41-9. Epub 2006 Dec 7.

PMID:
17158340
34.

Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.

Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J, Malavaud B, Cuvillier O.

Cancer Res. 2005 Dec 15;65(24):11667-75.

35.

Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.

Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O.

Leukemia. 2006 Jan;20(1):95-102.

PMID:
16281067
36.

Modest intracellular acidification suppresses death signaling in ouabain-treated cells.

Akimova OA, Pchejetski D, Hamet P, Orlov SN.

Pflugers Arch. 2006 Jan;451(4):569-78. Epub 2005 Jul 29.

PMID:
16052351
37.

Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression.

Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, Levade T, Moreau-Gachelin F.

Blood. 2005 Sep 1;106(5):1808-16. Epub 2005 May 12.

PMID:
15890687
38.

Na+/K+ pump and endothelial cell survival: [Na+]i/[K+]i-independent necrosis triggered by ouabain, and protection against apoptosis mediated by elevation of [Na+]i.

Orlov SN, Thorin-Trescases N, Pchejetski D, Taurin S, Farhat N, Tremblay J, Thorin E, Hamet P.

Pflugers Arch. 2004 Jun;448(3):335-45. Epub 2004 Apr 7.

PMID:
15069561
39.

Apoptosis in serum-deprived vascular smooth muscle cells: evidence for cell volume-independent mechanism.

Orlov SN, Pchejetski D, Taurin S, Thorin-Trescases N, Maximov GV, Pshezhetsky AV, Rubin AB, Hamet P.

Apoptosis. 2004 Jan;9(1):55-66.

PMID:
14739599
40.

Purinergic-induced signaling in C11-MDCK cells inhibits the secretory Na-K-Cl cotransporter.

Brindikova TA, Bourcier N, Torres B, Pchejetski D, Gekle M, Maximov GV, Montminy V, Insel PA, Orlov SN, Isenring P.

Am J Physiol Cell Physiol. 2003 Dec;285(6):C1445-53. Epub 2003 Aug 13.

41.

[3H]-thymidine labelling of DNA triggers apoptosis potentiated by E1A-adenoviral protein.

Orlov SN, Pchejetski DV, Sarkissian SD, Adarichev V, Taurin S, Pshezhetsky AV, Tremblay J, Maximov GV, deBlois D, Bennett MR, Hamet P.

Apoptosis. 2003 Mar;8(2):199-208.

PMID:
12766480
42.

Inhibition of Na+,K+-ATPase by ouabain triggers epithelial cell death independently of inversion of the [Na+]i/[K+]i ratio.

Pchejetski D, Taurin S, Der Sarkissian S, Lopina OD, Pshezhetsky AV, Tremblay J, deBlois D, Hamet P, Orlov SN.

Biochem Biophys Res Commun. 2003 Feb 14;301(3):735-44.

PMID:
12565842
43.

c-Fos expression in ouabain-treated vascular smooth muscle cells from rat aorta: evidence for an intracellular-sodium-mediated, calcium-independent mechanism.

Taurin S, Dulin NO, Pchejetski D, Grygorczyk R, Tremblay J, Hamet P, Orlov SN.

J Physiol. 2002 Sep 15;543(Pt 3):835-47.

Supplemental Content

Loading ...
Support Center